Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study

Suhayl Dhib-Jalbut; Sumandeep Sumandeep; Reuben Valenzuela; Kouichi Ito; Payal Patel; Mark Rametta

doi:10.1016/j.jneuroim.2012.08.012

Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study

Suhayl Dhib-Jalbut, Sumandeep Sumandeep, Reuben Valenzuela, Kouichi Ito, Payal Patel, Mark Rametta

Robert Wood Johnson Medical School (RWJMS), Neurology

Research output: Contribution to journal › Article › peer-review

16 Scopus citations

Abstract

We measured immune markers in subjects with multiple sclerosis (MS) treated with IFNβ-1b for 12. months. IL-17 levels were significantly higher at Month 6 (p=0.036) in relapsing subjects while BDNF levels were significantly higher at Month 3 (p=0.028) in relapse-free subjects. Change from baseline in IL-4 levels inversely correlated with disability score whereas change from baseline in IL-10/IFN-gamma ratio inversely correlated with occurrence of relapses. CXCR3 + CD8. + T-cells tended to be higher but declined with treatment in relapse-free compared with relapsing subjects. Findings show the potential of cytokine and neurotrophic factors as biomarkers of clinical response to IFNβ-1b.

Original language	English (US)
Pages (from-to)	131-140
Number of pages	10
Journal	Journal of Neuroimmunology
Volume	254
Issue number	1-2
DOIs	https://doi.org/10.1016/j.jneuroim.2012.08.012
State	Published - Jan 15 2013

All Science Journal Classification (ASJC) codes

Immunology and Allergy
Immunology
Neurology
Clinical Neurology

Keywords

Cytokines
Immune markers
Interferon beta-1b
Multiple sclerosis

Access to Document

10.1016/j.jneuroim.2012.08.012

Fingerprint Dive into the research topics of 'Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study'. Together they form a unique fingerprint.

Cite this

@article{10976adcb69140e79e2ef35ebec7064a,

title = "Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study",

abstract = "We measured immune markers in subjects with multiple sclerosis (MS) treated with IFNβ-1b for 12. months. IL-17 levels were significantly higher at Month 6 (p=0.036) in relapsing subjects while BDNF levels were significantly higher at Month 3 (p=0.028) in relapse-free subjects. Change from baseline in IL-4 levels inversely correlated with disability score whereas change from baseline in IL-10/IFN-gamma ratio inversely correlated with occurrence of relapses. CXCR3 + CD8. + T-cells tended to be higher but declined with treatment in relapse-free compared with relapsing subjects. Findings show the potential of cytokine and neurotrophic factors as biomarkers of clinical response to IFNβ-1b.",

keywords = "Cytokines, Immune markers, Interferon beta-1b, Multiple sclerosis",

author = "Suhayl Dhib-Jalbut and Sumandeep Sumandeep and Reuben Valenzuela and Kouichi Ito and Payal Patel and Mark Rametta",

year = "2013",

month = jan,

day = "15",

doi = "10.1016/j.jneuroim.2012.08.012",

language = "English (US)",

volume = "254",

pages = "131--140",

journal = "Journal of Neuroimmunology",

issn = "0165-5728",

publisher = "Elsevier",

number = "1-2",

}

Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study. / Dhib-Jalbut, Suhayl; Sumandeep, Sumandeep; Valenzuela, Reuben; Ito, Kouichi; Patel, Payal; Rametta, Mark.

In: Journal of Neuroimmunology, Vol. 254, No. 1-2, 15.01.2013, p. 131-140.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study

AU - Dhib-Jalbut, Suhayl

AU - Sumandeep, Sumandeep

AU - Valenzuela, Reuben

AU - Ito, Kouichi

AU - Patel, Payal

AU - Rametta, Mark

PY - 2013/1/15

Y1 - 2013/1/15

N2 - We measured immune markers in subjects with multiple sclerosis (MS) treated with IFNβ-1b for 12. months. IL-17 levels were significantly higher at Month 6 (p=0.036) in relapsing subjects while BDNF levels were significantly higher at Month 3 (p=0.028) in relapse-free subjects. Change from baseline in IL-4 levels inversely correlated with disability score whereas change from baseline in IL-10/IFN-gamma ratio inversely correlated with occurrence of relapses. CXCR3 + CD8. + T-cells tended to be higher but declined with treatment in relapse-free compared with relapsing subjects. Findings show the potential of cytokine and neurotrophic factors as biomarkers of clinical response to IFNβ-1b.

AB - We measured immune markers in subjects with multiple sclerosis (MS) treated with IFNβ-1b for 12. months. IL-17 levels were significantly higher at Month 6 (p=0.036) in relapsing subjects while BDNF levels were significantly higher at Month 3 (p=0.028) in relapse-free subjects. Change from baseline in IL-4 levels inversely correlated with disability score whereas change from baseline in IL-10/IFN-gamma ratio inversely correlated with occurrence of relapses. CXCR3 + CD8. + T-cells tended to be higher but declined with treatment in relapse-free compared with relapsing subjects. Findings show the potential of cytokine and neurotrophic factors as biomarkers of clinical response to IFNβ-1b.

KW - Cytokines

KW - Immune markers

KW - Interferon beta-1b

KW - Multiple sclerosis

UR - http://www.scopus.com/inward/record.url?scp=84871695430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871695430&partnerID=8YFLogxK

U2 - 10.1016/j.jneuroim.2012.08.012

DO - 10.1016/j.jneuroim.2012.08.012

M3 - Article

C2 - 22999187

AN - SCOPUS:84871695430

VL - 254

SP - 131

EP - 140

JO - Journal of Neuroimmunology

JF - Journal of Neuroimmunology

SN - 0165-5728

IS - 1-2

ER -